Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO GU 2019: Updates on treatment and management of bladder cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.02.19
Views: 3232
Rating:

Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim Bellmunt, Dr Andrea Necchi

Professor Matthew Galsky chairs a discussion with Professor Ananya Choudhury, Professor Joaquim Bellmunt and Dr Andrea Necchi on the latest data presented at ASCO GU 2019 in San Francisco, specifically focused on the treatment and management of urothelial cancer.

Conversations focused on signalling pathways and biomarkers, in particular FGFR3, and how expanding treatment options would benefit patients. The panel also discussed the impact of checkpoint blockade therapy, durability of immunotherapy responses, and highlighted the importance of biomarker robustness.

The outcomes of the RANGE study were also overviewed, and there was a general request to further stratify patients based on prognostic disease and treatment factors.

Adjuvant chemo- and radiotherapy in the treatment of local recurrence in bladder cancer
Developments in immune checkpoint blockade therapy for BCG-unresponsive bladder cancer
Toxicity profile of immune checkpoint blockade therapy for BCG-unresponsive patients
Current role of radiation in non-muscle invasive bladder cancer
Applications of antibody drug conjugates (ADCs) in urothelial cancer
Use of FGFR inhibitors and ADCs to target FGFR mutations
Cytotoxic chemotherapy and response rates
Robust and predictive biomarkers for patient stratification
Outcomes achieved in the RANGE trial
Further benefits of accurate patient stratification

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation